Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,171 Million (Mid Cap)
23.00
NA
2.28%
-0.04
9.66%
1.32
Revenue and Profits:
Net Sales:
837 Million
(Quarterly Results - Sep 2025)
Net Profit:
119 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.16%
0%
0.16%
6 Months
-10.96%
0%
-10.96%
1 Year
15.19%
0%
15.19%
2 Years
37.08%
0%
37.08%
3 Years
-11.37%
0%
-11.37%
4 Years
-8.81%
0%
-8.81%
5 Years
-31.46%
0%
-31.46%
Tianjin Ringpu Bio-technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.26%
EBIT Growth (5y)
5.92%
EBIT to Interest (avg)
14.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
0.47
Tax Ratio
10.67%
Dividend Payout Ratio
46.48%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.09%
ROE (avg)
9.50%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.13
EV to EBIT
22.12
EV to EBITDA
14.65
EV to Capital Employed
2.14
EV to Sales
2.66
PEG Ratio
NA
Dividend Yield
1.44%
ROCE (Latest)
9.67%
ROE (Latest)
9.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
836.70
886.00
-5.56%
Operating Profit (PBDIT) excl Other Income
105.00
180.60
-41.86%
Interest
8.90
9.20
-3.26%
Exceptional Items
1.20
18.00
-93.33%
Consolidate Net Profit
118.70
152.00
-21.91%
Operating Profit Margin (Excl OI)
125.50%
140.60%
-1.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -5.56% vs 8.61% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -21.91% vs 26.56% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,043.60
2,686.40
13.30%
Operating Profit (PBDIT) excl Other Income
573.30
517.40
10.80%
Interest
33.00
26.70
23.60%
Exceptional Items
-14.40
56.20
-125.62%
Consolidate Net Profit
329.80
515.00
-35.96%
Operating Profit Margin (Excl OI)
122.10%
139.00%
-1.69%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 13.30% vs 30.16% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -35.96% vs 37.77% in Dec 2023
About Tianjin Ringpu Bio-technology Co., Ltd. 
Tianjin Ringpu Bio-technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






